Consumers experiencing a gap in their Medicare Part D prescription drug coverage were more likely to forgo diabetes medications than those who had supplemental drug benefits. Business Week reports: "Medicare's so-called 'doughnut hole' could be forcing many American seniors to skip their diabetes medications, a new study suggests." The doughnut hole occurs because Medicare covers prescription drug costs up to a certain amount and then consumers must pick up the tab until they've hit another spending threshold. The study was based on 2006 data, "when Part D coverage included up to $2, 250 in total drug costs paid by both the patient and plan. ... The plan started paying again when people reached $3, 600 in total out-of-pocket drug expenses for the year." Researchers from Kaiser Permanente and the David Geffen School of Medicine at the University of California, Los Angeles, conducted the study that "looked at the effect of the doughnut hole on drug costs and diabetes medication adherence among participants in two large health systems that offered Medicare D plans.
On 11 January 1922 insulin was first used successfully in the treatment of diabetes. Insulin was discovered by Sir Frederick G Banting (pictured), Charles H Best and JJR Macleod at the University of Toronto in 1921 and it was subsequently purified by James B Collip. Before 1921, it was exceptional for people with Type 1 diabetes to live more than a year or two. One of the twentieth century's greatest medical discoveries, it remains the only effective treatment for people with Type 1 diabetes today. First successful use On 11 January 1922, Leonard Thompson, a 14-year-old boy with diabetes, who lay dying at the Toronto General Hospital, was given the first injection of insulin. However, the extract was so impure that Thompson suffered a severe allergic reaction, and further injections were cancelled. Over the next 12 days, James Collip worked day and night to improve the ox-pancreas extract, and a second dose was injected on the 23 January. This was completely successful, not only in having no obvious side-effects, but in completely eliminating the glycosuria sign of diabetes.
A new study claims that some older people with mild memory-loss are three times more likely to develop dementia if they also have diabetes. The research, by Alzheimer's Research Trust scientists at King's College London, published in the British Journal of Psychiatry, investigated the connection between mild cognitive impairment (MCI) in older people and dementia. Results The scientists followed 61 people aged 65 or over who had MCI over a period of four years. 16 (26 per cent) of the participants had diabetes. Results show that after four years, 19 (31 per cent) developed dementia, two (3 per cent) reverted to normal cognitive levels, and 40 (59 per cent) remained stable. Of those who progressed to dementia, seven had diabetes. "We have already seen a number of previous studies linking Type 2 diabetes to cognitive impairment and dementia and we already know that Type 2 diabetes is considered to be a risk factor for Alzheimer's disease, " said Dr Iain Frame, Director of Research at Diabetes UK.
In a year that will be remembered for swine flu and health care reform, the American Diabetes Association today released a year-in-review list on another topic that received major headlines in 2009: diabetes. The list focuses on achievements made in 2009 to stop diabetes. "Nearly 24 million Americans have diabetes and the numbers are not expected to decrease any time soon, " commented Larry Hausner, CEO, American Diabetes Association. "But even though the seriousness and scope of diabetes is daunting, the American Diabetes Association made many important strides in 2009 to help stem the tide of this deadly disease." Below are nine achievements in diabetes in 2009: 1) Reforming Health Care The Association took a lead role to ensure that pending federal health care reform legislation meets the needs of people with, and at risk for, diabetes. The Association advocated to end discrimination faced by people with diabetes in the insurance market. It also worked to include wellness and prevention provisions within health reform.
JDRF Forms Partnership With Animas To Develop First-Generation Automated System For Managing Type 1 Diabetes
The Juvenile Diabetes Research Foundation announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease -- the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated system to dispense insulin to patients based on real-time changes in blood sugar levels. Animas, a Johnson & Johnson company, is a leading manufacturer and distributor of insulin delivery and glucose management systems. JDRF is a global leader in research leading to better treatments and cures for type 1 diabetes. The objectives of the partnership, a major industry initiative within the JDRF Artificial Pancreas Project, are to develop an automated system to manage diabetes, conduct extensive clinical trials for safety and efficacy, and submit the product to the U.S. Food and Drug Administration for approval. "If successful, the development of this first-generation system would begin the process of automating how people with diabetes manage their blood sugar, " said Alan Lewis, PhD, President and Chief Executive Officer of JDRF.
Medical Care Technologies Inc. (OTCBB: MDCE) today announced that it has commenced trials to include Continuous Glucose Monitoring (CGM) to its current Tele-Health™ Suite. Management believes that by adding this function to its Tele-Health™ technology, users will be able to monitor and better control their diabetes while reducing costs. The Tele-Health™ Suite is a software that enables continuous interaction between the patient and the healthcare professionals for a more efficient and effective way of treating, supporting, managing and monitoring wellness. With this application we will focus on patients with diabetes. This unique solution will every day instruct patients to measure their blood glucose readings, as required to their long term condition. It can also provide medication reminders and ask the patient questions about their health. All this information is sent via the Internet to the patient's clinic for clinical triage which can then be managed by other healthcare professionals.
Diabetes mellitus is one of the most common chronic disease of the world and the prevalence of diabetes mellitus is over 10% in Taiwan. Gastroparesis is reported in 5% to 12% of diabetic patients. Superior mesenteric artery (SMA) syndrome is an uncommon disease resulting compression of the third portion of the duodenum from the superior mesenteric artery. However, SMA syndrome can cause the same symptoms as diabetic gastroparesis. A research team, led by Dr. Wen-Ming Wang from Kaohsiung Medical University Hospital reported a rare etiology of superior mesenteric artery syndrome. Their study was published on December 21, 2009 in the World Journal of Gastroenterology. Their report suggest that diabetic patients with gastrointestinal symptoms and bodyweight loss should be considered for SMA syndrome, despite the gastroparesis is the most common etiology. Computed tomography and upper gastrointestinal series are the reliable tools for diagnosis. Adequate nutrition supply is a useful treatment and the aim is bodyweight gain and symptom relief.
A new understanding and possible treatment for Type 2 diabetes could be on its way after one of the largest genetic studies to date discovered nine new genes linked to the condition. The genes and blood glucose levels of over 120, 000 volunteers were studied by scientists from 174 research centres across the world. A set of genes that control the body's response to glucose in the blood was identified. "An incredibly important finding" "This is an incredibly important finding, " said Jim Wilson, a geneticist from Edinburgh University involved in the study. "The discovery of these new genes influencing blood sugar levels is the first step on the important journey to developing new therapies for diabetes." A drug to prevent Type 2 diabetes? "It opens up a whole new area of research to find which proteins are 'druggable'. Genetics is like a can-opener: it allows us to get inside and understand what's going on." The study's scientists hope that in five to 10 years they will be able to identify which people have a genetic susceptibility to Type 2 diabetes, and to have a drug available that can prevent the condition developing.
PSivida CEO To Discuss Ocular Drug Delivery In Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 In London
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leader in the development of tiny, sustained-release drug delivery technologies, with two of the only three ophthalmic sustained-release delivery products approved by the FDA for treatment of back of the eye diseases, announced that its chief executive officer, Dr. Paul Ashton, will discuss ocular drug delivery in diabetic retinopathy during a presentation at the 6th Annual Diabetes Conference in London, on Friday, January 22. In his presentation Dr. Ashton will describe the barriers to clinically effective therapies in diabetic retinopathy and the difficulty of getting drugs to the back of the eye, where most diabetic eye disease manifests itself. He is expected to discuss emerging drug delivery technologies, including those under development at pSivida, which can help to get drugs directly to the area of the eye where they can be most effective in treating the underlying disease. As part of this presentation, Dr. Ashton is also expected to recap recent top-line results of the Phase 3 FAME™
In recent years, there has been a large increase in the prevalence of overweight and obese women of childbearing age, with approximately 51% of non-pregnant women ages 20 to 39 being classified as overweight or obese. A new article published in the journal Nursing for Women's Health finds that obesity in pregnant women is associated with pregnancy complications, birth defects, as well as a greater risk of childhood and adult obesity in infants born to obese mothers. Merrie Rebecca Walters, RN, and Julie Smith Taylor, PhD, RNC, WHNP-BC, reviewed the potential consequences of maternal obesity. Results show that obese women are more likely to have an infant with a neural tube defect, heart defects, or multiple anomalies than women with a normal BMI. Obese pregnant women also put themselves at a higher risk of pregnancy complications, including gestational diabetes, hypertension, preeclampsia, induction of labor, cesarean delivery, and postpartum hemorrhage, compared with women with normal pregnancy body mass indexes.